MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1172/jci204511

Медицинская библиотека · The Journal of clinical investigation · 2026

Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models.

Anand Sumit Kumar, Das Sandeep, Arias Fabio, Richard Koral Se, Rohilla Sumati, Ghrayeb Alia, McKinney M Peyton, Wang Lu, Tan Lin, Ding Jibin, Kumar Dhananjay, Pandey Nilesh, Lee Jennifer, Zhao Ying, Mohajan Suman, Male Gurranna, Nunez Kelley, Finney Alexandra C, Pearson-Gallion Brenna H, Gade Reethika, Maxie Jemiah, Liu Yu, Kaur Harpreet, Pandit Rajan, Ben Dhaou Cyrine, Eniafe Joseph, Zhang Xiaolu, Liu Zhipeng, Yurochko Andrew D, Garcia-Barrio Minerva T, Razani Babak, Chang Fei, Schopfer Francisco J, Huang Xin, Cai Bishuang, Gottlieb Eyal, Wen Bo, Sun Duxin, Liu Wanqing, Thevenot Paul T, Cohen Ari J, Zhang Jifeng, Chen Y Eugene, Orr A Wayne, Dhanesha Nirav, Yurdagul Arif, Rom Oren

СтатьяПеревод в очереди

Аннотация

Metabolic dysfunction-associated steatohepatitis (MASH) is rising globally despite recent therapeutic advances, highlighting the need to identify new targetable pathways. While dysregulated lipid and amino acid metabolism are established features of MASH, the interplay between these two metabolic pathways remains unexplored. Here, metabolomics of livers from humans and mice with MASH uncovered depletion of lipidated amino acids, where these two distinctive pathways converge. Notably, hepatic levels of N-oleoyl-leucine (C18:1-Leu) were inversely correlated with the severity of MASH-fibrosis. The C18:1-Leu-regulating enzyme, peptidase M20 domain containing 1 (PM20D1), was suppressed in MASH due to attenuated de novo transcription, and stable-isotope tracing confirmed impaired hepatic biosynthesis of C18:1-Leu in MASH. Hepatocyte-specific PM20D1 ablation lowered hepatic C18:1-Leu and exacerbated MASH, whereas hepatocyte-specific PM20D1 overexpression restored C18:1-Leu and ameliorated both MASH progression and established disease. Exogenous administration of C18:1-Leu similarly ameliorated MASH-fibrosis. In silico modeling, transcriptomics, metabolic flux analyses and hepatocyte-specific in vivo manipulations revealed that C18:1-Leu binds and activates peroxisome proliferator-activated receptor alpha to suppress C-C motif chemokine ligand 2, concurrently enhancing fatty acid β-oxidation and attenuating monocyte recruitment to reduce MASH-fibrosis. These findings highlight C18:1-Leu deficiency as a driver and a therapeutic target in MASH-fibrosis, warranting further clinical evaluation.

Для цитирования: Anand Sumit Kumar, Das Sandeep, Arias Fabio, Richard Koral Se, Rohilla Sumati, Ghrayeb Alia, McKinney M Peyton, Wang Lu, Tan Lin, Ding Jibin, Kumar Dhananjay, Pandey Nilesh, Lee Jennifer, Zhao Ying, Mohajan Suman, Male Gurranna, Nunez Kelley, Finney Alexandra C, Pearson-Gallion Brenna H, Gade Reethika, Maxie Jemiah, Liu Yu, Kaur Harpreet, Pandit Rajan, Ben Dhaou Cyrine, Eniafe Joseph, Zhang Xiaolu, Liu Zhipeng, Yurochko Andrew D, Garcia-Barrio Minerva T, Razani Babak, Chang Fei, Schopfer Francisco J, Huang Xin, Cai Bishuang, Gottlieb Eyal, Wen Bo, Sun Duxin, Liu Wanqing, Thevenot Paul T, Cohen Ari J, Zhang Jifeng, Chen Y Eugene, Orr A Wayne, Dhanesha Nirav, Yurdagul Arif, Rom Oren. Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models.. The Journal of clinical investigation. 2026. DOI: 10.1172/jci204511.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.